Parametrica Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Parametrica Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17,702	Closed	-$263K	–	132
2015 Q4	$263K	Buy	+17,702	New	+$296K	1.73%	22

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Parametrica Management's MNTA Position: Q1 2016 in Review

Parametrica Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2016, closing a stake of 17,702 shares — an estimated $263K sold.

Parametrica Management first reported a position in MNTA in Q4 2015 and held it in 1 quarter. The position peaked at $263K in Q4 2015. 148 funds tracked by Wall St. Rank hold MNTA as of Q1 2016.

Parametrica Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Parametrica Management sold 17,702 Momenta Pharmaceuticals, Inc. shares in Q1 2016, an estimated $263K.
Parametrica Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
Parametrica Management's Momenta Pharmaceuticals, Inc. position peaked at $263K in Q4 2015.
148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2016.

Based on Parametrica Management's 13F filing for Q1 2016, filed 5 May 2016.